Abstract
Background: Tumour necrosis factor α (TNFα) blockade using infliximab, a chimeric anti-TNFα antibody, is an effective treatment for both psoriasis and psoriatic arthritis (PsA). Objective: To analyse the early effects...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
